Lyons A J, Brennan P A
Head and Neck Unit, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT.
Maxillofacial Unit, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK.
Br J Oral Maxillofac Surg. 2017 Apr;55(3):230-234. doi: 10.1016/j.bjoms.2016.12.006. Epub 2016 Dec 27.
Pentoxifylline has been used to treat complications related to fibrosis for over 20 years. Formerly used to treat those after radiotherapy such as osteoradionecrosis (ORN), it is now being tried for medication-related osteonecrosis of the jaw (MRONJ), which can occur after prolonged use of bisphosphonates. We review theories on the formation of fibrosis in patients with ORN, discuss the pharmacology of pentoxifylline and vitamin E, and report published outcomes. To our knowledge no prospective randomised controlled trial has investigated the benefits of these agents in cases of ORN, but reported outcomes in many published case series are encouraging.
己酮可可碱用于治疗与纤维化相关的并发症已有20多年。它曾被用于治疗放疗后的患者，如放射性骨坏死（ORN），现在正被尝试用于治疗颌骨药物相关性骨坏死（MRONJ），后者可在长期使用双膦酸盐后发生。我们回顾了ORN患者纤维化形成的理论，讨论了己酮可可碱和维生素E的药理学，并报告了已发表的结果。据我们所知，尚无前瞻性随机对照试验研究这些药物对ORN病例的益处，但许多已发表病例系列中的报告结果令人鼓舞。
